Novel Clinician-Lead Intervention to Address Fear of Cancer Recurrence in Breast Cancer Survivors
Jia Liu(Garvan Institute of Medical Research), Jane Beith(The University of Sydney), Mun N. Hui(Chris O’Brien Lifehouse), Kim Tam Bui(Concord Repatriation General Hospital), Daniel Costa(The University of Sydney), Belinda E. Kiely(National Health and Medical Research Council), Anastasia Serafimovska(The University of Sydney), Phyllis Butow(Royal Prince Alfred Hospital), Catriona M. McNeil(Chris O’Brien Lifehouse), Annabel Goodwin(The University of Sydney)
Cited by 26
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Bisphosphonates and other bone agents for breast cancer
|Cochrane Database of Systematic Reviews|2017|359
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
Machine learning for multi-omics data integration in cancer
|iScience|2022|298